AHP Use Of Testing In Redux Follow-Ups Undermines Antimonitoring Stance
Executive Summary
American Home Products' use of echocardiographic monitoring in follow-up studies in patients who received the diet drugs Pondimin (fenfluramine) or Redux (dexfenfluramine) argues for a medical monitoring program for individuals who took the drug but are still asymptomatic, plaintiffs in a N.J. class action suit contend.
You may also be interested in...
Wyeth Found No Signal Of Valvular Heart Disease In Diet Drug AEs - Deitch
Wyeth-Ayerst identified no signal of valvular heart disease prior to 1997 in adverse drug event reports submitted for the weight loss agents Pondimin (fenfluramine) and Redux (dexfenfluramine), former Wyeth-Ayerst Senior VP-Medical Affairs Marc Deitch, MD, testified in the New Jersey diet drug class action suit.
Wyeth Found No Signal Of Valvular Heart Disease In Diet Drug AEs - Deitch
Wyeth-Ayerst identified no signal of valvular heart disease prior to 1997 in adverse drug event reports submitted for the weight loss agents Pondimin (fenfluramine) and Redux (dexfenfluramine), former Wyeth-Ayerst Senior VP-Medical Affairs Marc Deitch, MD, testified in the New Jersey diet drug class action suit.
Redux Echocardiographic Data Expected By Fall AHA Meeting - AHP
One-year echocardiographic data from a placebo-controlled cohort study of regular and sustained-release dexfenfluramine will be available by September, American Home Products Senior VP-Science and Technology Robert Levy, MD, told an investor teleconference Aug. 10.